Author:
Escherich G, ,Richards S,Stork L C,Vora A J
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference8 articles.
1. Harms DO, Gobel U, Spaar HJ, Graubner UB, Jorch N, Gutjahr P et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003; 102: 2736–2740.
2. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006; 368: 1339–1348.
3. Stork LC, Sather H, Hutchinson HJ, Broxson EH, Matloub Y, Yanofsky R et al. Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT ‘Triples’ (ITT) in children with SR-ALL: results of CCG-1952. Blood 2002; 100: 156a, A585.
4. Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood 2010; 115: 2740–2748.
5. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol 2009; 145: 376–388.
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献